Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nitric oxide as a therapeutic agent

C R Conti

    Clinical Cardiology
    |May 1, 1994
    PubMed
    Summary
    This summary is machine-generated.

    Inhaled nitric oxide offers selective pulmonary vasodilation, benefiting patients with conditions like ARDS and asthma. Further research is needed to assess potential adverse effects before routine use.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Treatment of mechanical valve thrombosis during pregnancy.

    Clinical cardiology·2007
    Same author

    Re-thinking angina.

    Clinical cardiology·2007
    Same author

    Inhibition of sodium-dependent calcium overload to treat myocardial ischemia.

    Clinical cardiology·2006
    Same author

    Clinical usefulness of electron beam computed tomography to detect coronary artery calcification.

    Clinical cardiology·2002
    Same author

    Prognosis after ICD implantation.

    Clinical cardiology·2001
    Same author

    How will INVEST and other hypertension trials change clinical practice?

    Clinical cardiology·2001
    Same journal

    Strauss-Defined LBBB Identifies Patients With Improved Outcomes After CRT-D: A Comparative Cohort Study.

    Clinical cardiology·2026
    Same journal

    Does Serum γKlotho Truly Provide Incremental Prognostic Value Beyond Established Risk Predictors in Multivessel Coronary Artery Disease?

    Clinical cardiology·2026
    Same journal

    Associations of the C-Reactive Protein-Albumin-Lymphocyte Index, Red Cell Distribution Width-Albumin Ratio, and Blood Urea Nitrogen-Albumin Ratio With All-Cause and Cardiovascular Mortality Among Adults With Preclinical Heart Failure.

    Clinical cardiology·2026
    Same journal

    Real-World National Databases Versus Hypothesis-Driven Cohort Studies: A Reply to the Critique on the TURK-HF Registry Design.

    Clinical cardiology·2026
    Same journal

    Comment on Wang et al.: Unaddressed Multiple Comparisons Risk Inflating Type, Error in Cardiovascular Specialty Nursing Research.

    Clinical cardiology·2026
    Same journal

    Methodological and Statistical Confounding in Comparing Patient-Reported Outcomes Between Cardioversion and Ablation for Atrial Fibrillation.

    Clinical cardiology·2026
    See all related articles

    Area of Science:

    • Pulmonary Medicine
    • Pharmacology

    Background:

    • Inhaled nitric oxide (iNO) exhibits rapid vasorelaxant properties, primarily in the pulmonary circulation.
    • iNO's interaction with hemoglobin leads to a short half-life, limiting systemic effects.

    Discussion:

    • The selective action of iNO on pulmonary circulation and bronchial smooth muscle avoids systemic hypotension.
    • This selectivity makes iNO a potential therapeutic agent for conditions such as Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Lung Disease (COLD), and asthma.

    Key Insights:

    • Patients with increased postoperative pulmonary vascular resistance may experience transient benefits from iNO.
    • The localized effect in the lungs is a key advantage, preserving systemic vascular resistance.

    Outlook:

    Related Experiment Videos

    • Further investigation into the potential adverse effects of iNO is crucial.
    • Clinical trials are necessary to establish the safety and efficacy of iNO for routine therapeutic use.